Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Published:2021-08-11 Issue:21 Volume:27 Page:5818-5827
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Saura Cristina^ORCID,Matito Judit,Oliveira Mafalda^ORCID,Wildiers Hans^ORCID,Brufksy Adam M.,Waters Simon H.^ORCID,Hurvitz Sara A.,Moy Beverly,Kim Sung-Bae,Gradishar William J.,Queiroz Geraldo Silva,Cronemberger Eduardo^ORCID,Wallweber Gerald J.,Bebchuk Judith,Keyvanjah Kiana,Lalani Alshad S.,Bryce Richard^ORCID,Vivancos Ana,Eli Lisa D.,Delaloge Suzette

Funder

Puma Biotechnology Inc.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

2. Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study;MedComm;2024-06-19

3. Clinical implications and management strategies of resistance to anti-HER2 antibodies in breast cancer;Overcoming Cancers Resistant to HER-2 Antibodies;2024

4. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review;Annals of Oncology;2023-12

5. Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data;Translational Oncology;2023-11